top of page

Mwandishi:

Mhariri:

Imeboershwa:

ULY CLINIC

ULY CLINIC

17 Februari 2026, 14:31:27

Stevens Johnson Syndrome (SJS)
Stevens Johnson Syndrome (SJS)

Stevens Johnson Syndrome (SJS)

Stevens–Johnson Syndrome (SJS) is a rare but serious acute mucocutaneous hypersensitivity reaction, most commonly triggered by medications. It is characterized by epidermal necrosis leading to blistering and detachment of the skin and mucous membranes.

SJS represents the milder end of the SJS/TEN spectrum:

  • SJS: <10% body surface area detachment

  • SJS/TEN overlap: 10–30%

  • TEN: >30%

This condition is a medical emergency due to risk of dehydration, sepsis, and organ failure.


Etiology

Drug-induced (most common)

  • Sulfonamides

  • Anticonvulsants (carbamazepine, phenytoin, phenobarbital, lamotrigine)

  • Allopurinol

  • Nevirapine

  • NSAIDs (oxicam group)

  • Penicillins and cephalosporins


Infectious triggers (more common in children)

  • Mycoplasma pneumoniae

  • Viral infections (HSV, HIV)


Pathophysiology

Immune-mediated cytotoxic reaction:

  • Drug antigen activates cytotoxic T-cells

  • Keratinocyte apoptosis occurs

  • Epidermis separates from dermis

  • Leads to blistering and erosions of skin and mucosa


Risk Factors

  • HIV infection

  • Previous drug reactions

  • Polypharmacy

  • Genetic susceptibility (HLA-related)

  • Malignancy

  • Autoimmune disease


Signs and Symptoms

Prodromal phase (1–3 days)

  • Fever

  • Malaise

  • Arthralgia

  • Sore throat

  • Burning eyes


Cutaneous findings

  • Abrupt erythema multiform-like rash

  • Target lesions evolving to blisters

  • Skin tenderness

  • Peeling epidermis


Mucosal involvement

Oral
  • Painful erosions

  • Hemorrhagic crusted lips

  • Necrotic white pseudomembrane


Ocular (70–90%)
  • Erosive conjunctivitis

  • Photophobia

  • Risk of corneal scarring


Genital (60–70%)
  • Painful erosions

  • Dysuria


Diagnostic Criteria

Clinical diagnosis based on:

  • Sudden erythema multiform-like rash

  • Prodrome with fever, malaise, arthralgia

  • Hemorrhagic crusted lips and oral erosions

  • Eye involvement (erosive conjunctivitis)

  • Genital mucosal erosions

  • Skin detachment <10% BSA


Investigations


Laboratory tests

  • Full blood count

  • Urea and electrolytes

  • Liver function tests

  • Blood glucose

  • CRP


Infection assessment

  • Blood cultures if febrile

  • Swabs from erosions


Confirmatory test

  • Skin biopsy → epidermal necrosis


Treatment


Admission and Monitoring

  • Immediate hospital admission

  • Close monitoring of fluids and electrolytes

  • Nutritional support

  • Temperature regulation


Non-Pharmacological Treatment

  • Stop suspected drug immediately

  • Maintain hydration

  • Gentle wound care (non-adhesive dressings)

  • Oral care with saline rinses

  • Eye lubrication and ophthalmology review

  • Prevent secondary infection

  • Pain control


Pharmacological Treatment

  • Early systemic corticosteroids (short course, early stage only)

  • Topical antiseptic dressings

  • Treat secondary infections promptly with antibiotics

  • IV fluids for dehydration

Late corticosteroid use increases infection risk and delays healing


Complications


Acute

  • Dehydration

  • Sepsis

  • Electrolyte imbalance

  • Pneumonia


Long-term

  • Ocular scarring → blindness

  • Genital adhesions

  • Chronic dry eyes

  • Skin pigmentation changes


Prevention

  • Avoid re-exposure to culprit drug

  • Record allergy in medical file

  • Patient drug-alert card

  • Careful prescribing in HIV patients

  • Pharmacovigilance reporting


References

  1. Tanzania Ministry of Health. Standard Treatment Guidelines & National Essential Medicines List (STG/NEMLIT). 6th ed. Dodoma: MoH; 2023.

  2. Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for management of SJS/TEN. Br J Dermatol. 2016;174(6):1194–1227.

  3. Harr T, French LE. Stevens–Johnson syndrome and toxic epidermal necrolysis. Orphanet J Rare Dis. 2010;5:39.

  4. World Health Organization. Guidelines for management of severe cutaneous adverse reactions. Geneva: WHO; 2018.

  5. Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th ed. Elsevier; 2018.


Imeandikwa;

3 Novemba 2020, 12:38:00

bottom of page